You have requested to receive a Daily Digest e-mail from U.S. Food & Drug Administration (FDA).
Message: 1
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 10 Apr 2008 11:10:10 -0500 (CDT)
Subject: Cracker Barrel Issues Allergy Alert on Mislabeled Chocolate-Covered Peanuts and Almonds (April 9)
Cracker Barrel Issues Allergy Alert on Mislabeled Chocolate-Covered Peanuts and Almonds (April 9)
Thu, 10 Apr 2008 10:15:00 -0500
Cracker Barrel Old Country Store, Inc. is recalling 5-ounce bags of chocolate-covered almonds and 5-ounce bags of chocolate double-dipped peanuts because the packaging is labeled incorrectly.
Message: 2
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 10 Apr 2008 13:44:49 -0500 (CDT)
Subject: FDA MedWatch- CellCept (mycophenolate mofetil) and Myfortic (mycophenolate acid)-Possible Development Of Progressive Multifocal Leukoencephalopathy
  |
FDA informed healthcare professionals that the Agency is investigating a potential association between the use of CellCept and Myfortic, medicines used to prevent organ rejection, and the development of progressive multifocal leukoencephalopathy (PML), a life-threatening disease. PML is a rare disorder that affects the central nervous system usually occurring in patients with immune systems suppressed by disease or medicines. FDA is reviewing data submitted by Roche, including postmarketing reports it has received of PML in patients who took CellCept or Myfortic, and the proposed revisions to the CellCept prescribing information. FDA has asked Novartis, the maker of Myfortic, for data on PML cases and to revise the Myfortic prescribing information to include the same information about PML included in the CellCept prescribing information. FDA anticipates it may take about 2 months to complete its review of the postmarketing reports and the proposed revisions to the prescribing information. As soon as the review is completed, FDA will communicate the conclusions and recommendations to the public.
Until further information is available, patients and healthcare professionals should be aware of the possibility of PML, such as localized neurologic signs and symptoms in the setting of a suppressed immune system, including during therapy with CellCept and Myfortic.
Read the complete 2008 MedWatch Safety Summary, including a link to the FDA Communication About an Ongoing Safety Review regarding this issue and prior MedWatch alerts regarding these products at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#mycophenolate
Message: 3
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Thu, 10 Apr 2008 14:59:02 -0500 (CDT)
Subject: FDA MedWatch - Total Body Formula, Total Body Mega Formula found to contain hazardous levels of selenium
| |
[UPDATE] The FDA notified healthcare professionals and patients that it has found hazardous levels of selenium in samples of certain flavors of the dietary supplement products "Total Body Formula" and "Total Body Mega Formula." Analyses of samples by FDA have found most of the samples contain extremely high levels of selenium -- up to 200 times the amount of selenium indicated on the labels of the products. The FDA has received 43 reports of persons from nine states who experienced serious adverse reactions using these products. The adverse reactions generally occurred after five to 10 days of daily ingestion of the product, and included significant hair loss, muscle cramps, diarrhea, joint pain, deformed fingernails, and fatigue. Consumers should stop taking the products and consult their healthcare professional if they experience any adverse events associated with the use of the products.
Read the complete MedWatch 2008 safety summary, including a link to the FDA News Release, at:
http://www.fda.gov/medwatch/safety/2008/safety08.htm#TotalBody
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com.
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
No comments:
Post a Comment